Clinigen appoints Nick Keher as new CFO

AIM-listed pharmaceutical and services company Clinigen Group has appointed Nick Keher as its new chief financial officer with effect from 19 March.

Keher will replace Martin Abell, who has resigned and is due to leave the business at the end of March.

Keher joins from Royal Bank of Canada, where he was a managing director and Head of the European Healthcare equity research team. He has covered the European healthcare space for over eight years at both RBC and Investec.

He started his career at Lloyd's Pharmacy, registering as a pharmacist before joining GlaxoSmithKline, where he worked within the group's R&D, UK commercial operations and global manufacturing & supply strategy finance teams.

Chief executive officer Shaun Chilton said: "Nick brings considerable pharmacy and pharmaceutical experience as well as financial expertise, both as an accountant and from working in the financial markets.

"He has a deep knowledge and insight of our business through his research and analysis of Clinigen since its IPO in 2012. He will be a key addition to the executive management team."

At 1125 GMT, the shares were down 1.3% to 800.50p.